135 search results for: type 2 inflammation

Skin Barrier Dysfunction and <b>Type</b> <b>2</b> <b>Inflammation</b> in Atopic Dermatitis

videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

5 min

Dermatology

Learn more about how chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis

IRS-ISIAN <b>2</b>0<b>2</b>4 | Targeting <b>Type</b> <b>2</b> <b>Inflammation</b>: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

9 min

Rhinology

Prof. Joaquim Mullol reports on biologic improvements in sense of smell and nasal congestion in patients with and without a history of endoscopic sinus surgery.

Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

5 min

Type 2 Inflammation

Discover how barrier dysfunction, neuroimmune dysregulation, and type 2 inflammation contribute to the pathophysiology of various diseases

How Does Protective <b>Type</b> <b>2</b> Immunity Become Harmful <b>Type</b> <b>2</b> <b>Inflammation</b>?

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

<b>Type</b> <b>2</b> <b>Inflammation</b> in AD Manifestations in Skin and Body

expert video

Type 2 Inflammation in AD Manifestations in Skin and Body

6 min

Dermatology

Dr. Ramien discusses the role of type 2 inflammation in the pathophysiology of atopic dermatitis, and highlights the association of atopic dermatitis with systemic diseases and comorbidities.

What Do We Know About <b>Type</b> <b>2</b> <b>Inflammation</b> in COPD?

expert video

What Do We Know About Type 2 Inflammation in COPD?

1 min

Pulmonology

Join global expert Dr. Michael Wechsler as he discusses type 2 inflammation in COPD.

The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Atopic Dermatitis

expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

1 min

Dermatology

The impact of type 2 inflammation and barrier dysfunction in the pathogenesis of chronic disease in atopic dermatitis.

Clinical Presentations in AD, PN, and CSU: Role of <b>Type</b> <b>2</b> <b>Inflammation</b>

expert video

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

20 min

Dermatology

Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Skin Barrier Dysfunction in Atopic Dermatitis

expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

2 min

Dermatology

Dr. Robert Bissonnette highlights the role of type 2 inflammation in skin barrier dysfunction in atopic dermatitis.

Multidisciplinary Partnership for <b>Type</b> <b>2</b> Inflammatory Diseases

expert video

Multidisciplinary Partnership for Type 2 Inflammatory Diseases

18 min

Type 2 Inflammation

Drs. Thomas Casale, Mario Castro and Profs. Peter Hellings, Ian Pavord, Ulrike von Arnim, and Stephan Weidinger discuss multidisciplinary care

FeNO as a Biomarker for <b>Type</b> <b>2</b> Asthma

expert video

FeNO as a Biomarker for Type 2 Asthma

16 min

Pulmonology

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ThailandChange country/region